Precision medicine in hemato-oncology – treatment of refractory multiple myeloma with massive extramedullary involvement using BRAF/MEK inhibitors
This case illustrates the potential of precision therapy in the treatment of MM with BRAFV600E mutation. Panel sequencing and minimally invasive approaches to diagnosis and disease monitoring can significantly contribute to personalized care and a better understanding of disease dynamics.
Authors
- Marta Krejčí (ORCID: https://orcid.org/0000-0001-5216-8778)
- Andrea Marečková (ORCID: https://orcid.org/0000-0001-9096-9680)
- Kateřina Menšíková (ORCID: https://orcid.org/0000-0003-4834-3160)
- Eva Ondroušková (ORCID: https://orcid.org/0000-0003-0830-0692)
- I. Boichuk (ORCID: https://orcid.org/0000-0002-4385-081X)
- Marek Borský (ORCID: https://orcid.org/0000-0001-5803-5941)
- Zdeněk Adam
- Michal Brada
- Jana Kotašková (ORCID: https://orcid.org/0000-0003-1672-7346)
- Viera Sandecká (ORCID: https://orcid.org/0000-0003-4074-8497)
- Vladimír Nekuda (ORCID: https://orcid.org/0000-0003-0644-8378)
- Viera Hrabčáková
- Martin Štork (ORCID: https://orcid.org/0000-0002-7072-8537)
- Milan Krtička (ORCID: https://orcid.org/0000-0002-7101-1896)
- Marie Jarošová
- Pavel Šlampa
- Luděk Pour
- Zuzana Jelínková
- Nela Sendlerová (ORCID: https://orcid.org/0009-0002-3702-7971)
- Michaela Bilčíková
- Lenka Vojtková
- Johana Mayerová
Publication Details
- Journal
- Klinicka onkologie
- Published
- 2025-10-15
- DOI
- https://doi.org/10.48095/ccko2025390
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00